Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2020

View Archived Issues

Phase I/II data presented for the SIIPL-PCV vaccine candidate

MRAP2 is accessory after the fact for appetite regulation

Human proteomics study gives new AD insights

Sanifit opens enrollment in phase III study of SNF-472 for calciphylaxis

Novartis opens phase III study of TQJ-230 in patients with cardiovascular disease

Oncolytic viruses 'wrapped' with tumor cell membranes show improved infectivity in cancer cells

Stem cell-based approach to spinal cord injuries developed

AMO Pharma opens enrollment in pivotal trial of AMO-02 for congenital myotonic dystrophy

BioMarin to initiate clinical testing of BMN-307 gene therapy

New preclinical data support PBI-05204 as a potential treatment for GBM

Topline data presented from TRILOGY 1 study of CaPre

RNF208 as a prognostic biomarker in TNBC

PTC Therapeutics describes new compounds for treating Huntington's disease

Jacobio-Beta Pharmaceuticals, Beijing Jacobio Pharmaceuticals patent BET inhibitors

Remdesivir as a potential new therapeutic option for MERS-CoV

Methylphenidate improves executive functioning in patients with VCI

MSD KK receives approval for Pifeltro for treating HIV-1 infection

New cardiac sarcomere inhibitors discovered at Cytokinetics

Zhejiang Vimgreen Pharma discloses adenosine A2A receptor antagonists

FDA clears IND for phase Ib/II study of AVB-500 in clear cell renal cell carcinoma

FDA approves Valtoco as acute treatment for seizures

Abeona initiates phase III study of EB-101 in recessive dystrophic epidermolysis bullosa

Neos studies NT-0502 in pilot phase I trial for chronic sialorrhea

Lilly opens enrollment in phase I study of CD73 inhibitor LY-3475070 in advanced cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...